Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$100,000.00

Ex vivo Interleukin-10 Therapy for the Repair of Donor Lungs for Transplantation

EF 2009-10

Résumé
Lung transplantation has been established as a life-saving therapy for many patients with end stage respiratory disease. However, the current organ shortage means that 15% of patients die before receiving a lung transplant. This shortage is due in large part to the fact that only 15% of donated lungs are currently deemed suitable for transplantation. The majority are too inflamed to be used safely. Improvement in the utilization rate of donated lungs would significantly address the organ shortage problem. Interleukin-10 (IL-10) is a signaling molecule which shows promising anti-inflammatory effects. Unfortunately, when given to the donor body, it is degraded in minutes and cannot exert its effect. We have tried to deliver IL-10 to lungs after removal from the body, but the cold temperature used to preserve the lungs limits its effect. Previously, we have used gene therapy to genetically modify the donor lung to make IL-10 before it is removed from the body. Although effective, this technique prolongs the time the organs need to stay within the donor body, allowing further injury to occur. Also, gene therapy requires the use of a virus delivery system, which is logistically cumbersome. Recently, we developed a technique of keeping lungs "alive" outside of the body at body temperature called ex vivo lung perfusion (EVLP). We have found that IL-10 is not degraded when added to lungs on this system. The goal of this research project is to use the technique of EVLP to identify the best way of delivering IL-10 therapy to inflamed donor lungs. To do this, we will first develop a pig injury model to mimic inflamed donor lungs. Then, we will compare whether delivery of IL-10 into the airway, into the bloodstream, or via gene therapy is most effective to repair these inflamed pig lungs. As a future goal, the most effective method will be used to start a human clinical trial to increase the use of donor lungs and ultimately to decrease waiting list mortality.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
197244
Name
Yeung Jonathan C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Ex vivo Interleukin-10 Therapy for the Repair of Donor Lungs for Transplantation
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cytokine; Ex Vivo Perfusion; Gene Therapy; Inflammation; Interleukin-10; Ischemia-Reperfusion Injury; Lung Transplantation; Thoracic Surgery
Abstract
Lung transplantation has been established as a life-saving therapy for many patients with end stage respiratory disease. However, the current organ shortage means that 15% of patients die before receiving a lung transplant. This shortage is due in large part to the fact that only 15% of donated lungs are currently deemed suitable for transplantation. The majority are too inflamed to be used safely. Improvement in the utilization rate of donated lungs would significantly address the organ shortage problem. Interleukin-10 (IL-10) is a signaling molecule which shows promising anti-inflammatory effects. Unfortunately, when given to the donor body, it is degraded in minutes and cannot exert its effect. We have tried to deliver IL-10 to lungs after removal from the body, but the cold temperature used to preserve the lungs limits its effect. Previously, we have used gene therapy to genetically modify the donor lung to make IL-10 before it is removed from the body. Although effective, this technique prolongs the time the organs need to stay within the donor body, allowing further injury to occur. Also, gene therapy requires the use of a virus delivery system, which is logistically cumbersome. Recently, we developed a technique of keeping lungs "alive" outside of the body at body temperature called ex vivo lung perfusion (EVLP). We have found that IL-10 is not degraded when added to lungs on this system. The goal of this research project is to use the technique of EVLP to identify the best way of delivering IL-10 therapy to inflamed donor lungs. To do this, we will first develop a pig injury model to mimic inflamed donor lungs. Then, we will compare whether delivery of IL-10 into the airway, into the bloodstream, or via gene therapy is most effective to repair these inflamed pig lungs. As a future goal, the most effective method will be used to start a human clinical trial to increase the use of donor lungs and ultimately to decrease waiting list mortality.
Competitiondate
200911
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Yeung, Jonathan C
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~